发明授权
US5241083A Process for converting the 13-.alpha.-hydroxy group of avermectin
aglycones
失效
转化阿维菌素糖苷配基的13-α-羟基的方法
- 专利标题: Process for converting the 13-.alpha.-hydroxy group of avermectin aglycones
- 专利标题(中): 转化阿维菌素糖苷配基的13-α-羟基的方法
-
申请号: US907429申请日: 1992-07-01
-
公开(公告)号: US5241083A公开(公告)日: 1993-08-31
- 发明人: Timothy Bill , Chris H. Senanayake , Robert D. Larsen , Sheo B. Singh , Thomas R. Vernhoeven
- 申请人: Timothy Bill , Chris H. Senanayake , Robert D. Larsen , Sheo B. Singh , Thomas R. Vernhoeven
- 申请人地址: NJ Rahway
- 专利权人: Merck & Co., Inc.
- 当前专利权人: Merck & Co., Inc.
- 当前专利权人地址: NJ Rahway
- 主分类号: C07D493/22
- IPC分类号: C07D493/22
摘要:
The natural stereochemistry at the 13-position of avermectin aglycones, normally .alpha.-oriented or below the plane of the molecule, is inverted or epimerized into the .beta.-position. The procedure starts with the avermectin aglycone compounds where the 13.alpha.-hydroxy group is activated to a mesylate leaving group. The resultant 13-.alpha.-mesylate is then displaced with a cesium carboxylate and one equivalent of the respective carboxylic acid, ending with the ester group being converted to the 13-.beta.-hydroxy configuration by transesterification in high yield.
公开/授权文献
- US6019473A Switchable format film projection system 公开/授权日:2000-02-01
信息查询